Chalfin Heather J, Fabian Elizabeth, Mangold Leslie, Yeater David B, Pienta Kenneth J, Partin Alan W
James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
BJU Int. 2016 Dec;118(6):864-868. doi: 10.1111/bju.13606. Epub 2016 Aug 29.
In the current era of individualized medicine, a biorepository of human samples is essential to support clinical and translational research. There have been limited efforts in this arena within the field of urology, as cost, logistical and ethical issues represent significant deterrents to biobanking. The Johns Hopkins Brady Urological Institute Biorepository was founded in 1994 as a resource to facilitate discovery. Since its inception, the biorepository has enabled numerous research endeavours including pivotal trials leading to the regulatory approval of four diagnostic tests for prostate cancer. In the present review, we discuss the current state of biobanking within urology, outline the specific ethical and financial challenges to biobanking as well as solutions, and describe the operations of a successful urological biorepository.
在当前的个性化医疗时代，人类样本生物样本库对于支持临床和转化研究至关重要。在泌尿外科领域，这方面的努力有限，因为成本、后勤和伦理问题对生物样本库构成了重大阻碍。约翰·霍普金斯布瑞迪泌尿外科研究所生物样本库成立于1994年，作为促进发现的资源。自成立以来，该生物样本库助力了众多研究工作，包括多项关键试验，这些试验促成了四项前列腺癌诊断测试获得监管批准。在本综述中，我们讨论了泌尿外科生物样本库的现状，概述了生物样本库面临的具体伦理和财务挑战以及解决方案，并描述了一个成功的泌尿外科生物样本库的运作情况。
